We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+26.22%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$475M
AUM Growth
+$226M
Cap. Flow
+$193M
Cap. Flow %
40.57%
Top 10 Hldgs %
41.72%
Holding
154
New
62
Increased
25
Reduced
13
Closed
48

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$7.96M
2
AMGN icon
Amgen
AMGN
+$5.99M
3
AZTA icon
Azenta
AZTA
+$5.35M
4
ESTA icon
Establishment Labs
ESTA
+$5.33M
5
CNC icon
Centene
CNC
+$5.26M

Sector Composition

Rank Sector Weight
1 Healthcare 35.48%
2 Industrials 0.59%
3 Technology 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$821B
$62.5M 13.15%
215,000
+202,500
+1,620% +$57.7M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$83B
$37.9M 7.98%
225,000
+180,000
+400% +$30.4M
LIVN icon
3
CALL
LivaNova
LIVN
$4.69B
$26M 5.48%
210,000
+15,000
+8% +$1.77M
XLV icon
4
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.8B
$11.9M 2.5%
125,000
+65,000
+108% +$5.87M
ICUI icon
5
ICU Medical
ICUI
$4.3B
$11.7M 2.46%
41,319
+17,319
+72% +$5.07M
INSP icon
6
Inspire Medical Systems
INSP
$1.85B
$10.2M 2.16%
243,493
+43,213
+22% +$2.03M
MDT icon
7
CALL
Medtronic
MDT
$110B
$9.84M 2.07%
+100,000
New +$9.25M
BSX icon
8
Boston Scientific
BSX
$71.1B
$9.74M 2.05%
252,925
+227,925
+912% +$7.96M
NVO
9
CALL
Novo Nordisk
NVO
$196B
$9.43M 1.98%
+400,000
New +$9.76M
ICUI icon
10
CALL
ICU Medical
ICUI
$4.3B
$9.05M 1.9%
32,000
-3,000
-9% -$879K
LIVN icon
11
LivaNova
LIVN
$4.69B
$8.79M 1.85%
70,871
+821
+1% +$96.8K
FXH icon
12
PUT
First Trust Health Care AlphaDEX Fund
FXH
$1.06B
$8.49M 1.79%
+100,000
New +$7.98M
MDT icon
13
Medtronic
MDT
$110B
$7.97M 1.68%
81,027
+31,027
+62% +$2.87M
ABT icon
14
CALL
Abbott
ABT
$182B
$7.34M 1.54%
+100,000
New +$6.57M
DXCM icon
15
CALL
DexCom
DXCM
$32.8B
$7.15M 1.5%
+200,000
New +$6.2M
ZBH icon
16
CALL
Zimmer Biomet
ZBH
$18.5B
$6.57M 1.38%
+51,500
New +$6.12M
DXCM icon
17
DexCom
DXCM
$32.8B
$6.52M 1.37%
182,240
+82,240
+82% +$2.55M
NSTG
18
DELISTED
NanoString Technologies, Inc.
NSTG
$6.36M 1.34%
356,494
+158,377
+80% +$2.31M
AMGN icon
19
Amgen
AMGN
$210B
$6.3M 1.32%
+30,373
New +$5.99M
AMGN icon
20
PUT
Amgen
AMGN
$210B
$6.22M 1.31%
+30,000
New +$5.91M
STAA icon
21
STAAR Surgical
STAA
$1.2B
$5.83M 1.23%
121,556
+21,556
+22% +$883K
VRAY
22
DELISTED
ViewRay, Inc.
VRAY
$5.81M 1.22%
620,839
+187,524
+43% +$1.84M
XENT
23
CALL
DELISTED
Intersect ENT, Inc
XENT
$5.75M 1.21%
+200,000
New +$6.01M
AZTA icon
24
Azenta
AZTA
$1.39B
$5.7M 1.2%
+162,676
New +$5.35M
CNC icon
25
Centene
CNC
$31.7B
$5.49M 1.15%
+75,810
New +$5.26M

Similar funds

Pura Vida Investments's Q3 2018 Portfolio in Review

As of Q3 2018, Pura Vida Investments held 154 positions worth $475M, up 91% from $250M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Pura Vida Investments deployed $193M of net new capital in Q3 2018, opening 62 new positions and adding to 25 existing holdings. Its largest new stake was Amgen: 30,373 shares worth $6.3M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 37% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $2.36M trimmed.

  • Pura Vida Investments's largest Q3 2018 buy was Amgen: 30,373 shares worth $6.3M.
  • Pura Vida Investments added most to Boston Scientific in Q3 2018, an estimated $7.96M increase.
  • Pura Vida Investments's biggest Q3 2018 reduction was Madrigal Pharmaceuticals, cutting an estimated $2.36M.
  • Pura Vida Investments fully exited Sientra, Inc. in Q3 2018, selling an estimated $3.59M.
  • Pura Vida Investments's ten largest holdings make up 42% of its $475M portfolio in Q3 2018.
  • Pura Vida Investments opened 62 new positions and closed 48 in Q3 2018.
  • Pura Vida Investments's portfolio value rose 91% quarter-over-quarter to $475M.

Based on Pura Vida Investments's 13F filing for Q3 2018, filed 14 Nov 2018.